Abstract
Objective: Recently a randomized placebo-controlled phase III trial of biodegradable polymers containing carmustine has demonstrated a significant survival benefit for patients treated with local chemotherapy. A local chemotherapy applied directly to the resection cavity may act directly on residual tumor cells in adjacent brain possibly leading to a local control of the tumor and increased survival.
Methods: We have analyzed the pattern of recurrence using serial MRI studies of 24 patients treated with GLIADEL® Wafers or placebo wafers following resection of glioblastomas.
Results: Of 24 patients 11 received carmustine wafers and 13 placebo. The age distribution and Karnowsky performance scores of the two populations were not different. However, the median survival (14.7 versus 9.5 months; P = 0.007) and the time to neurological deterioration (12.9 ± 4.85 vs. 9.4 ± 2.73 months; P = 0.035) was significantly longer in the treatment group versus the placebo treated control. Preoperative and follow up MRI studies were evaluated in a blinded fashion. Out of 24 patients that entered the analysis 11 showed clearance of all contrast enhancement following resection of glioblastomas. Seventeen tumors progressed locally and 7 showed different patterns of distant failure. Within the carmustine treated group 8 patients showed a local treatment failure with recurrent tumors immediately adjacent to the resection cavity or progression form a residual tumor. Three patients showed a multifocal distant and local pattern of failure after complete or subtotal removal. In no case the local chemotherapy resulted in a distant recurrence only. However, the time to radiographic progression was 165.1 ± 80.75 days for the GLIADEL® Wafer group and 101.9 ± 43.06 days for the placebo group (P = 0.023).
Conclusion: In this subgroup analysis of a phase III trial population both the clinical progression and radiological progression were significantly delayed in patients treated with local chemotherapy, resulting in an increased survival time. Local chemotherapy with carmustine containing wafer implants did not result in an altered pattern of recurrence and did not promote multifocal patterns of recurrence.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Brem H, Tamargo RJ, Olivi A, Pinn M, Weingart JD, Wharam M, Epstein JI: Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. J Neurosurg 80: 283-290, 1994
Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, Morawetz R, Schold SC: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345: 1008-1012, 1995
Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke P, Whittle I, Jääskeläinen J, Ram Z (2002): A phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers in patients with primary malignant Glioma. Neuro-Oncology 5: 79-88, 2003
Westphal M, Giese A: Local control of gliomas: the next best step — a good step? Front Radiat Ther Oncol 33: 214-226, 1999
Giese A, Westphal M: Glioma invasion in the central nervous system. Neurosurgery 39: 235-252, 1996
Giese A, Bjerkvig R, Westphal M, Berens ME: The cost of migration: invasion of malignant gliomas and implications for treatment. JCO 21: 1624-1636, 2003
Quigley MR, Maroon JC: The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas. Neurosurgery 29: 385-389, 1991
Albert FK, Forsting M, Sartor K, Adams H-P, Kunze S: Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 34: 45-61, 1994
Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95: 190-198, 2001
Ammirati M, Vick N, Liao Y, Ciric I, Mikhael M: Effect of extend of surgical resection on survival and quality of life in patients with supratentorial glioblastoma and anaplastic astrocytomas. Neurosurgery 21: 201-206, 1987
Ciric I, Vick NA, Mikhael MA, Cozzens J, Eller T, Walsh A: Aggressive surgery for malignant supratentorial gliomas. Clin Neurosurg 36: 375-383, 1990
de Tribolet N, Frankhauser H: Surgery in the treatment of malignant glioma: current status and future perspectives. In: Karim ABMF, Laws ER Jr (eds) Glioma. Springer, Berlin, 1991, pp 93-105
Salcman M: The value of cytoreductive surgery. Clin Neurosurg 41: 464-488, 1994
Vecht CJ, Avezaat CJJ, van Putten WLJ, Eijkenboom WMH, Stefanko SZ: The influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospective analysis in 243 patients. J Neurol Neurosurg Psychiatry 53: 466-471, 1990
Burger PC, Dubois PJ, Schold SC, Smith KR, Odom GL, Crafts DC, Giangaspero F: Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg 58: 159-169, 1983
Gaspar LE, Fisher BJ, MacDonald DR, Leber DV, Halperin EC, Schold SC, Cairncross JG: Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Rad Oncol 24: 55-57, 1992
Darlymple JS, Parisi JE, Roche PC, Ziesmer SC, Scheithauer BW, Kelly PJ: Changes in proliferating cell nuclear antigen expression in glioblastoma multiforme cells along a stereotactic biopsy trajectory. Neurosurgery 35: 1036-1045, 1994
Schiffer D, Cavalla P, Dutto A, Borsotti L: Cell Proliferation and invasion in malignant gliomas. Anticancer Res 17: 61-70, 1997
Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O, Unsgaard G, Kuurne T: Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 41: 44-49, 1997
Reulen HJ, Graber S, Huber P, Ito U: Factors affecting the extension of peritumoural brain edema. A CT study. Acta Neurochir 95: 19-24, 1988
Barnard RO, Geddes JF: The incidence of multifocal cerebral gliomas. Cancer 60: 1519-1531, 1987
Budka H, Prodeka I, Reisner T, Zeiler K: Diagnostic and pathomorphological aspects of glioma multiplicity. Neurosurg Rev 3: 233-241, 1980
Puchner MJ, Herrmann HD, Berger J, Cristante L: Surgery, tamoxifen, carboplatin, and radiotherapy in the treatment of newly diagnosed glioblastoma patients. J Neuro-Oncol 49: 147-155, 2000
Silbergeld DL, Rostomily RC, Alvord EC Jr: The cause of death in patients with glioblastoma is multifactorial: clinical factors and autopsy findings in 117 cases of supratentorial glioblastomas in adults. J Neuro-Oncol 10: 179-185, 1991
Sipos EP, Tyler B, Piantadosi S, Burger PC, Brem H: Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemother Pharmacol 39: 383-389, 1997
Brem H, Mahaley MS, Vick NA, Black KL, Schold SC Jr, Burger PC, Friedman AH, Ciric IS, Eller TW, Cozzens JW, Kenealy JN: Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 74: 44144-44146, 1991
Prager JM, Grenier Y, Cozzens JW, Chiowanich P, Gorey MT, Meyer JR: Serial CT and MR imaging of carmustine wafers. Am J Neuroradiol 21: 119-123, 2000
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Giese, A., Kucinski, T., Knopp, U. et al. Pattern of Recurrence following Local Chemotherapy with Biodegradable Carmustine (BCNU) Implants in Patients with Glioblastoma. J Neurooncol 66, 351–360 (2004). https://doi.org/10.1023/B:NEON.0000014539.90077.db
Issue Date:
DOI: https://doi.org/10.1023/B:NEON.0000014539.90077.db